Novartis Takes Cardiovascular Setbacks In Stride After Poor Showing At ACC
Novartis' strategy to expand its cardiovascular and metabolics business in advance of the patent expiry of its blockbuster Diovan included running a lot of clinical trials to add indications and amass outcomes data. But studies designed to expand use also have the potential to disappoint, as was the case for several trials presented at the American College of Cardiology annual meeting